{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:13:29Z","timestamp":1740107609140,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Italian Ministry of Health"},{"DOI":"10.13039\/501100015822","name":"Fondazione Roma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015822","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Aims<\/jats:title>\n<jats:p>To evaluate the timing and spectral-domain optical coherence tomography (SD-OCT) features of diabetic macular oedema (DME) recurrence according to baseline OCT patterns in patients treated with dexamethasone implant (DEX-I).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This is a retrospective observational study (72 eyes\/65 patients). Best-corrected visual acuity, timing of DME recurrence, and SD-OCT pattern [intraretinal cysts (IRC), IRC plus subretinal fluid (mixed), external limiting membrane (ELM), ellipsoid (IS\/OS) layer integrity] were assessed at baseline and monthly until first DME recurrence.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Forty-two (58.3%) and 30 (41.6%) DME eyes had an IRC and mixed DME pattern at baseline, respectively. Twenty-four out of thirty mixed eyes (80%) relapsed without subretinal fluid. At baseline, mixed eyes showed similar changes in ELM and IS\/OS (60 and 76.6% of eyes, respectively) versus IRC eyes (42.8 and 80.9% of eyes). After DME recurrence, more mixed eyes at baseline showed ELM and IS\/OS changes (63.3 and 86.6%) than IRC eyes (50 and 76.2%). 33.3% of mixed eyes had DME recurrence at\u2009\u2265\u20096\u00a0months from first DEX-I implant versus 19% of IRC eyes.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Mixed DME eyes were treated with DEX-I relapse later and more frequently without subretinal fluid than IRC eyes. SD-OCT characteristics of different DME patterns at baseline can predict morphological features and timing of DME recurrence.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00592-020-01504-w","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T09:02:56Z","timestamp":1582966976000},"page":"867-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Baseline SD-OCT characteristics of diabetic macular oedema patterns can predict morphological features and timing of recurrence in patients treated with dexamethasone intravitreal implants"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3656-1689","authenticated-orcid":false,"given":"Chiara M.","family":"Eandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"De Geronimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Sole","family":"Polito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Neri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Le Mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Varano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariacristina","family":"Parravano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,29]]},"reference":[{"key":"1504_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2008.10.001","volume":"54","author":"N Bhagat","year":"2009","unstructured":"Bhagat N, Grigorian RA, Tutela A, Zarbin MA (2009) Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 54:1\u201332","journal-title":"Surv Ophthalmol"},{"key":"1504_CR2","doi-asserted-by":"publisher","first-page":"e0159553","DOI":"10.1371\/journal.pone.0159553","volume":"11","author":"L Zhang","year":"2016","unstructured":"Zhang L, Wang W, Gao Y, Lan J, Xie L (2016) The efficacy and safety of current treatments in diabetic macular edema: a systematic review and network meta-analysis. PLoS ONE 11:e0159553","journal-title":"PLoS ONE"},{"key":"1504_CR3","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/S0161-6420(84)34102-1","volume":"91","author":"R Klein","year":"1984","unstructured":"Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91:1464\u20131474","journal-title":"Ophthalmology"},{"key":"1504_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","volume":"116","author":"H Funatsu","year":"2009","unstructured":"Funatsu H, Noma H, Mimura T, Eguchi S, Hori S (2009) Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116:73\u201379","journal-title":"Ophthalmology"},{"key":"1504_CR5","doi-asserted-by":"publisher","first-page":"10836","DOI":"10.1073\/pnas.96.19.10836","volume":"96","author":"K Miyamoto","year":"1999","unstructured":"Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP (1999) Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96:10836\u201310841","journal-title":"Proc Natl Acad Sci USA"},{"key":"1504_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12886-018-0779-1","volume":"18","author":"Y He","year":"2018","unstructured":"He Y, Ren XJ, Hu BJ, Lam WC, Li XR (2018) A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmol 18:121","journal-title":"BMC Ophthalmol"},{"key":"1504_CR7","doi-asserted-by":"publisher","first-page":"e002269","DOI":"10.1136\/bmjopen-2012-002269","volume":"3","author":"JA Ford","year":"2013","unstructured":"Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N (2013) Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open 3:e002269","journal-title":"BMJ Open"},{"key":"1504_CR8","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ, Ride, Rise Research Group (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120:2013\u20132022","journal-title":"Ophthalmology"},{"key":"1504_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2415-12-11","volume":"12","author":"BA Nguyen-Khoa","year":"2012","unstructured":"Nguyen-Khoa BA, Goehring EL, Werther W, Fung AE, Do DV, Apte RS, Jones JK (2012) Hospitalized cardiovascular events in patients with diabetic macular edema. BMC Ophthalmol 12:11","journal-title":"BMC Ophthalmol"},{"key":"1504_CR10","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1167\/iovs.04-0905","volume":"46","author":"H Tamura","year":"2005","unstructured":"Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N (2005) Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 46:1440\u20131444","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1504_CR11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1248\/bpb.31.1541","volume":"31","author":"K Wang","year":"2008","unstructured":"Wang K, Wang Y, Gao L, Li X, Li M, Guo J (2008) Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 31:1541\u20131546","journal-title":"Biol Pharm Bull"},{"key":"1504_CR12","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1167\/iovs.10-6387","volume":"52","author":"JE Chang-Lin","year":"2011","unstructured":"Chang-Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, Zhang KM, Kuppermann BD, Robinson MR, Whitcup SM, Welty DF (2011) Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 52:4605\u20134609","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1504_CR13","first-page":"317","volume":"6","author":"N Haghjou","year":"2011","unstructured":"Haghjou N, Soheilian M, Abdekhodaie MJ (2011) Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res 6:317\u2013329","journal-title":"J Ophthalmic Vis Res"},{"key":"1504_CR14","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex Mead Study Group (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121:1904\u20131914","journal-title":"Ophthalmology"},{"key":"1504_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2147\/DMSO.S73540","volume":"8","author":"Z Cebeci","year":"2015","unstructured":"Cebeci Z, Kir N (2015) Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant. Diabetes Metab Syndr Obes 8:555\u2013566","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1504_CR16","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2147\/OPTH.S79948","volume":"9","author":"PU Dugel","year":"2015","unstructured":"Dugel PU, Bandello F, Loewenstein A (2015) Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol 9:1321\u20131335","journal-title":"Clin Ophthalmol"},{"key":"1504_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/eye.2015.246","volume":"30","author":"J Chhablani","year":"2016","unstructured":"Chhablani J, Bansal P, Veritti D, Sambhana S, Sarao V, Pichi F, Carrai P, Massaro D, Lembo A, Mansour AM, Banker A, Gupta SR, Hamam R, Lanzetta P (2016) Dexamethasone implant in diabetic macular edema in real-life situations. Eye (Lond) 30:426\u2013430","journal-title":"Eye (Lond)"},{"key":"1504_CR18","first-page":"1255","volume":"9","author":"WC Lam","year":"2015","unstructured":"Lam WC, Albiani DA, Yoganathan P, Chen JC, Kherani A, Maberley DA, Oliver A, Rabinovitch T, Sheidow TG, Tourville E, Wittenberg LA, Sigouin C, Baptiste DC (2015) Real-world assessment of intravitreal dexamethasone implant (0.7\u00a0mg) in patients with macular edema: the CHROME study. Clin Ophthalmol 9:1255\u20131268","journal-title":"Clin Ophthalmol"},{"key":"1504_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12886-018-1022-9","volume":"19","author":"V Castro-Navarro","year":"2019","unstructured":"Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C, Monferrer-Adsuara C, Hernandez-Bel L, Montero-Hernandez J (2019) Intravitreal dexamethasone implant Ozurdex(R) in naive and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol 19:15","journal-title":"BMC Ophthalmol"},{"key":"1504_CR20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/eye.2013.17","volume":"27","author":"A Koytak","year":"2013","unstructured":"Koytak A, Altinisik M, Sogutlu Sari E, Artunay O, Umurhan Akkan JC, Tuncer K (2013) Effect of a single intravitreal bevacizumab injection on different optical coherence tomographic patterns of diabetic macular oedema. Eye (Lond) 27:716\u2013721","journal-title":"Eye (Lond)"},{"key":"1504_CR21","doi-asserted-by":"publisher","first-page":"8035013","DOI":"10.1155\/2017\/8035013","volume":"2017","author":"A Herbaut","year":"2017","unstructured":"Herbaut A, Fajnkuchen F, Qu-Knafo L, Nghiem-Buffet S, Bodaghi B, Giocanti-Auregan A (2017) Switching to aflibercept in diabetic macular edema not responding to ranibizumab and\/or intravitreal dexamethasone implant. J Ophthalmol 2017:8035013","journal-title":"J Ophthalmol"},{"key":"1504_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ajo.2017.10.004","volume":"184","author":"H Al-Khersan","year":"2017","unstructured":"Al-Khersan H, Hariprasad SM, Chhablani J, Dex Implant Study Group (2017) Early response to intravitreal dexamethasone implant therapy in diabetic macular edema may predict visual outcome. Am J Ophthalmol 184:121\u2013128","journal-title":"Am J Ophthalmol"},{"key":"1504_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ophtha.2017.08.031","volume":"125","author":"D Zur","year":"2018","unstructured":"Zur D, Iglicki M, Busch C, Mariussi A, Mariussi M, Loewenstein A, International Retina Group (2018) OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology 125:267\u2013275","journal-title":"Ophthalmology"},{"key":"1504_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/IAE.0b013e3182a48917","volume":"34","author":"S Sonoda","year":"2014","unstructured":"Sonoda S, Sakamoto T, Yamashita T, Shirasawa M, Otsuka H, Sonoda Y (2014) Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema. Retina 34:741\u2013748","journal-title":"Retina"},{"key":"1504_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ajo.2007.09.029","volume":"145","author":"D Gaucher","year":"2008","unstructured":"Gaucher D, Sebah C, Erginay A, Haouchine B, Tadayoni R, Gaudric A, Massin P (2008) Optical coherence tomography features during the evolution of serous retinal detachment in patients with diabetic macular edema. Am J Ophthalmol 145:289\u2013296","journal-title":"Am J Ophthalmol"},{"key":"1504_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/IAE.0000000000002196","volume":"39","author":"M Iglicki","year":"2019","unstructured":"Iglicki M, Busch C, Zur D, Okada M, Mariussi M, Chhablani JK, Cebeci Z, Fraser-Bell S, Chaikitmongkol V, Couturier A, Giancipoli E, Lupidi M, Rodriguez-Valdes PJ, Rehak M, Fung AT, Goldstein M, Loewenstein A (2019) Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: the International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study. Retina 39:44\u201351","journal-title":"Retina"},{"key":"1504_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000371770","volume":"233","author":"JJ Escobar-Barranco","year":"2015","unstructured":"Escobar-Barranco JJ, Pina-Marin B, Fernandez-Bonet M (2015) Dexamethasone implants in patients with naive or refractory diffuse diabetic macular edema. Ophthalmologica 233:176\u2013185","journal-title":"Ophthalmologica"},{"key":"1504_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000492132","volume":"241","author":"P Mello Filho","year":"2019","unstructured":"Mello Filho P, Andrade G, Maia A, Maia M, Biccas Neto L, Muralha Neto A, Moura Brasil O, Minelli E, Dalloul C, Iglicki M (2019) Effectiveness and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: a real-world experience. Ophthalmologica 241:9\u201316","journal-title":"Ophthalmologica"},{"key":"1504_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3341\/kjo.2017.0041","volume":"32","author":"H Lee","year":"2018","unstructured":"Lee H, Kang KE, Chung H, Kim HC (2018) Prognostic factors for functional and anatomic outcomes in patients with diabetic macular edema treated with dexamethasone implant. Korean J Ophthalmol 32:116\u2013125","journal-title":"Korean J Ophthalmol"},{"key":"1504_CR30","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1167\/iovs.18-26215","volume":"60","author":"M Figueras-Roca","year":"2019","unstructured":"Figueras-Roca M, Sala-Puigdollers A, Zarranz-Ventura J, Alba-Linero C, Alforja S, Esquinas C, Molins B, Adan A (2019) Anatomic response to intravitreal dexamethasone implant and baseline aqueous humor cytokine levels in diabetic macular edema. Invest Ophthalmol Vis Sci 60:1336\u20131343","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1504_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, Jonas J, Larsen M, Tadayoni R, Loewenstein A (2017) Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 237:185\u2013222","journal-title":"Ophthalmologica"},{"key":"1504_CR32","unstructured":"Guidelines for Diabetic Eye Care. Updated (2017). http:\/\/www.icoph.org\/downloads\/ICOGuidelinesforDiabeticEyeCare.pdf. Accessed 8 Apr 2019"},{"key":"1504_CR33","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2015.12.012","volume":"123","author":"S Fraser-Bell","year":"2016","unstructured":"Fraser-Bell S, Lim LL, Campain A, Mehta H, Aroney C, Bryant J, Li J, Quin GJ, McAllister IL, Gillies MC (2016) Bevacizumab or dexamethasone implants for DME: 2-year results (The BEVORDEX Study). Ophthalmology 123:1399\u20131401","journal-title":"Ophthalmology"},{"key":"1504_CR34","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","volume":"121","author":"MC Gillies","year":"2014","unstructured":"Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, Goodwin S, Aroney C, McAllister IL, Fraser-Bell S (2014) A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 121:2473\u20132481","journal-title":"Ophthalmology"},{"key":"1504_CR35","first-page":"491835","volume":"2013","author":"S Vujosevic","year":"2013","unstructured":"Vujosevic S, Bini S, Midena G, Berton M, Pilotto E, Midena E (2013) Hyperreflective\u00a0intraretinal spots in diabetics without and with nonproliferative diabetic retinopathy: an in vivo study using spectral domain OCT. J Diabetes Res 2013:491835","journal-title":"J Diabetes Res"},{"issue":"11","key":"1504_CR36","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","volume":"132","author":"JK Sun","year":"2014","unstructured":"Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS, Aiello LP (2014) Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol 132(11):1309\u20131316","journal-title":"JAMA Ophthalmol"},{"key":"1504_CR37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4103\/0301-4738.111184","volume":"62","author":"D Zhu","year":"2014","unstructured":"Zhu D, Zhu H, Wang C, Yang D (2014) Intraocular soluble intracellular adhesion molecule-1 correlates with subretinal fluid height of diabetic macular edema. Indian J Ophthalmol 62:295\u2013298","journal-title":"Indian J Ophthalmol"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-020-01504-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-020-01504-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-020-01504-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:23:46Z","timestamp":1614471826000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-020-01504-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1504"],"URL":"https:\/\/doi.org\/10.1007\/s00592-020-01504-w","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"type":"print","value":"0940-5429"},{"type":"electronic","value":"1432-5233"}],"subject":[],"published":{"date-parts":[[2020,2,29]]},"assertion":[{"value":"16 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MP reports personal fees from Allergan, Bayer, Novartis, outside of the submitted work. YLM reports personal fees from Allergan and Novartis, outside of the submitted work. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional review board approval for a retrospective chart review was obtained from the individual centres (University of Torino, IRCCS-Fondazione Bietti in Rome, University of Siena, and Rothschild Foundation in Paris), as required by local guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights disclosure"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent disclosure"}}]}}